Skip to main content

Table 1 Cytokine secretion

From: Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases

  HUVECs IXT HUVECs + IXT
Interleukin-3 181 ± 15 240 ± 20* 229 ± 24
Interleukin-6 9,610 ± 808 9,201 ± 7,368 59,567 ± 3,801***,‡
Interleukin-8 16,525 ± 1,697 36,998 ± 5,957** 35,128 ± 9,227
CXCL5 205 ± 34 7,893 ± 4,630 9,385 ± 1,710**
CCL1 83 ± 3 28 ± 8*** 204 ± 39*,†
CCL7 67 ± 11 10,563 ± 1,748** 13,901 ± 3821**
MIF 3,765 ± 761 5,234 ± 1,556 5,364 ± 1,114
VEGF 15 ± 4 428 ± 275 95 ± 57
PDGF-BB 225 ± 29 34 ± 2*** 1,065 ± 345*,†
EGF 171 ± 51 17 ± 5* 256 ± 74
HGF 51 ± 8 5,752 ± 2,324* 271 ± 40**,†
PlFG 1,218 ± 210 1,123 ± 476 2,648 ± 477*
Angiogenin 17,13 ± 237 33,102 ± 7,300** 8,722 ± 3,384*,†
Osteoprotegerin 434 ± 5 8,041 ± 5,992 2,049 ± 1,468
  1. Cytokines were quantified in supernatants from tumor necrosis factor alpha pretreated HUVECs, HUVECS co-cultured with ixmyelocel-T, and ixmyelocel-T (n ≥3). Values are presented as mean ± standard error of the mean relative to control. EGF, epidermal growth factor; HGF, hepatocyte growth factor; HUVEC, human umbilical vein endothelial cell; IXT, ixmyelocel-T; MIF, macrophage migration inhibitory factor; PDGF, platelet-derived growth factor; PlGF, placental growth factor; VEGF, vascular endothelial growth factor. *P <0.05, **P <0.01, ***P <0.001 versus HUVEC. P <0.05, P <0.01 versus IXT.